Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2018 | Waldenström’s macroglobulinemia highlights from ASH 2018

Jonas Paludo • 4 Dec 2018
ASH 2018
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib Venetoclax

Jonas Paludo, MD, of the Mayo Clinic, Rochester, MN, shares his view on the highlights for Waldenström’s macroglobulinemia from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Jonas Paludo

Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapy
2:36
Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapy
Jonas Paludo • 28 Oct 2022
The importance of studying RNA expression in rare diseases such as WM
0:57
The importance of studying RNA expression in rare diseases such as WM
Jonas Paludo • 28 Oct 2022
Long non-coding RNA expression in IgM-MGUS and Waldenström’s macroglobulinemia
1:50
Long non-coding RNA expression in IgM-MGUS and Waldenström’s macroglobulinemia
Jonas Paludo • 28 Oct 2022
Association between depth of response and survival in Waldenström’s
0:56
Association between depth of response and survival in Waldenström’s
Jonas Paludo • 6 Dec 2018

Related Videos

Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Jonas Paludo • 6 Dec 2025
Is the biology of T-cell malignancies too complex for a single-agent immunotherapy approach?
0:51
Is the biology of T-cell malignancies too complex for a single-agent immunotherapy approach?
Jonas Paludo • 8 Dec 2025
Interim analysis of a Phase II study of the GLOVe regimen in untreated, high-risk MCL
3:24
Interim analysis of a Phase II study of the GLOVe regimen in untreated, high-risk MCL
Jonas Paludo • 6 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Jonas Paludo • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals